Kwang Dong Pharmaceutical Co., Ltd. (009290.KS)
KRW 5670.0
(0.0%)
KRW 5670.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 490.01 Billion KRW | 27.28% |
| 2022 | 384.97 Billion KRW | 7.96% |
| 2021 | 356.6 Billion KRW | 8.57% |
| 2020 | 328.46 Billion KRW | -4.88% |
| 2019 | 345.31 Billion KRW | 14.64% |
| 2018 | 301.21 Billion KRW | -1.69% |
| 2017 | 306.39 Billion KRW | 9.39% |
| 2016 | 280.1 Billion KRW | -2.08% |
| 2015 | 286.05 Billion KRW | 123.25% |
| 2014 | 128.13 Billion KRW | -4.98% |
| 2013 | 134.85 Billion KRW | 10.39% |
| 2012 | 122.16 Billion KRW | 69.28% |
| 2011 | 72.16 Billion KRW | 1.81% |
| 2010 | 70.87 Billion KRW | 13.95% |
| 2009 | 62.2 Billion KRW | -4.5% |
| 2008 | 65.13 Billion KRW | -6.86% |
| 2007 | 69.93 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 528.9 Billion KRW | 5.51% |
| 2024 Q1 | 501.3 Billion KRW | 2.3% |
| 2023 Q2 | 426.39 Billion KRW | 6.75% |
| 2023 Q3 | 440.51 Billion KRW | 3.31% |
| 2023 Q4 | 490.01 Billion KRW | 11.24% |
| 2023 FY | 490.01 Billion KRW | 27.28% |
| 2023 Q1 | 399.43 Billion KRW | 3.75% |
| 2022 Q4 | 384.97 Billion KRW | 6.09% |
| 2022 Q3 | 362.88 Billion KRW | 0.42% |
| 2022 Q2 | 361.37 Billion KRW | 13.51% |
| 2022 FY | 384.97 Billion KRW | 7.96% |
| 2022 Q1 | 318.35 Billion KRW | -10.72% |
| 2021 Q2 | 345.52 Billion KRW | 7.58% |
| 2021 Q3 | 350.31 Billion KRW | 1.38% |
| 2021 FY | 356.6 Billion KRW | 8.57% |
| 2021 Q1 | 321.19 Billion KRW | -2.21% |
| 2021 Q4 | 356.6 Billion KRW | 1.8% |
| 2020 Q3 | 315.57 Billion KRW | -3.77% |
| 2020 Q4 | 328.46 Billion KRW | 4.08% |
| 2020 Q2 | 327.92 Billion KRW | 0.47% |
| 2020 FY | 328.46 Billion KRW | -4.88% |
| 2020 Q1 | 326.4 Billion KRW | -5.48% |
| 2019 Q3 | 316.2 Billion KRW | -2.04% |
| 2019 Q1 | 321.78 Billion KRW | 6.83% |
| 2019 FY | 345.31 Billion KRW | 14.64% |
| 2019 Q2 | 322.79 Billion KRW | 0.31% |
| 2019 Q4 | 345.31 Billion KRW | 9.21% |
| 2018 Q1 | 305.29 Billion KRW | -0.36% |
| 2018 Q3 | 305.83 Billion KRW | -0.68% |
| 2018 FY | 301.21 Billion KRW | -1.69% |
| 2018 Q4 | 301.21 Billion KRW | -1.51% |
| 2018 Q2 | 307.93 Billion KRW | 0.87% |
| 2017 FY | 306.39 Billion KRW | 9.39% |
| 2017 Q2 | 298.34 Billion KRW | 2.45% |
| 2017 Q4 | 306.39 Billion KRW | 0.5% |
| 2017 Q3 | 304.86 Billion KRW | 2.18% |
| 2017 Q1 | 291.21 Billion KRW | 3.97% |
| 2016 Q1 | 288.12 Billion KRW | 0.72% |
| 2016 Q2 | 285.6 Billion KRW | -0.87% |
| 2016 Q3 | 286.93 Billion KRW | 0.47% |
| 2016 Q4 | 280.1 Billion KRW | -2.38% |
| 2016 FY | 280.1 Billion KRW | -2.08% |
| 2015 Q1 | 298.38 Billion KRW | 132.87% |
| 2015 Q4 | 286.05 Billion KRW | -5.02% |
| 2015 Q3 | 301.16 Billion KRW | 5.2% |
| 2015 FY | 286.05 Billion KRW | 123.25% |
| 2015 Q2 | 286.28 Billion KRW | -4.06% |
| 2014 Q3 | 132.41 Billion KRW | -9.39% |
| 2014 Q2 | 146.13 Billion KRW | 7.07% |
| 2014 FY | 128.13 Billion KRW | -4.98% |
| 2014 Q4 | 128.13 Billion KRW | -3.23% |
| 2014 Q1 | 136.48 Billion KRW | 1.21% |
| 2013 Q4 | 134.85 Billion KRW | 1.49% |
| 2013 Q2 | 138.46 Billion KRW | -0.37% |
| 2013 Q1 | 138.97 Billion KRW | 13.76% |
| 2013 FY | 134.85 Billion KRW | 10.39% |
| 2013 Q3 | 132.86 Billion KRW | -4.04% |
| 2012 Q1 | 68.35 Billion KRW | 0.0% |
| 2012 FY | 122.16 Billion KRW | 69.28% |
| 2012 Q4 | 122.16 Billion KRW | 0.0% |
| 2011 FY | 72.16 Billion KRW | 1.81% |
| 2011 Q3 | 65.93 Billion KRW | -7.14% |
| 2011 Q2 | 71 Billion KRW | 0.75% |
| 2011 Q1 | 70.47 Billion KRW | -0.57% |
| 2010 Q4 | 70.87 Billion KRW | 6.31% |
| 2010 Q3 | 66.67 Billion KRW | 2.0% |
| 2010 FY | 70.87 Billion KRW | 13.95% |
| 2010 Q1 | 63.05 Billion KRW | 1.37% |
| 2010 Q2 | 65.36 Billion KRW | 3.66% |
| 2009 Q1 | 65.44 Billion KRW | 0.47% |
| 2009 FY | 62.2 Billion KRW | -4.5% |
| 2009 Q4 | 62.2 Billion KRW | -3.96% |
| 2009 Q3 | 64.77 Billion KRW | -2.09% |
| 2009 Q2 | 66.15 Billion KRW | 1.08% |
| 2008 Q1 | 63.85 Billion KRW | -8.69% |
| 2008 Q2 | 70.79 Billion KRW | 10.86% |
| 2008 Q3 | 69.68 Billion KRW | -1.56% |
| 2008 Q4 | 65.13 Billion KRW | -6.53% |
| 2008 FY | 65.13 Billion KRW | -6.86% |
| 2007 Q1 | 70.53 Billion KRW | 0.0% |
| 2007 FY | 69.93 Billion KRW | 0.0% |
| 2007 Q3 | 77.16 Billion KRW | 6.16% |
| 2007 Q2 | 72.68 Billion KRW | 3.04% |
| 2007 Q4 | 69.93 Billion KRW | -9.37% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -529.376% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 47.298% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 30.7% |
| HANDOK Inc. | 449.7 Billion KRW | -8.964% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | -471.981% |
| Yuhan Corporation | 712.33 Billion KRW | 31.21% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | 22.455% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -2982.946% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 42.474% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -815.433% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -138.017% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -551.872% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | -231.554% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | -596.036% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -529.376% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -1244.865% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | -95.109% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | -122.024% |
| JW Holdings Corporation | 827.51 Billion KRW | 40.784% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | -12.134% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | 16.492% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -29.089% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -517.918% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -600.35% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | -101.776% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | -48.358% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -529.376% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 42.89% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -29.089% |
| Yuhan Corporation | 712.33 Billion KRW | 31.21% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | -2.555% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | -257.76% |
| Suheung Co., Ltd. | 516.66 Billion KRW | 5.158% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -29.089% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | -217.09% |
| Korea United Pharm Inc. | 89.96 Billion KRW | -444.675% |
| CKD Bio Corp. | 170.76 Billion KRW | -186.962% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | -101.046% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | -210.813% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -1039.07% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -517.918% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 22.529% |
| Boryung Corporation | 373.1 Billion KRW | -31.334% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | -135.363% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -138.017% |
| JW Lifescience Corporation | 96.44 Billion KRW | -408.09% |